Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + navitoclax
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trametinib + navitoclax is an investigational combination therapy being evaluated by the National Cancer Institute (NCI) for the treatment of advanced solid tumors harboring KRAS or NRAS mutations. Trametinib is a highly selective, reversible, allosteric inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase kinase), which are key components of the MAPK/ERK signaling pathway. Navitoclax (ABT-263) is an orally bioavailable small molecule that inhibits the pro-survival BCL-2 family proteins, including BCL-2, BCL-XL, and BCL-W. By combining a MEK inhibitor with a BCL-2 family inhibitor, the regimen aims to induce apoptosis and overcome the resistance often seen with MEK inhibitor monotherapy in RAS-mutated cancers. Clinical trials have focused on indications such as pancreatic, colorectal, non-small cell lung, and gynecologic cancers.
- Other names
- trametinib and navitoclaxtrametinib/navitoclax
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)BCL2L2 (BCL-2-like protein 2)
Beyond the preview
Go deeper on trametinib + navitoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + navitoclax.